Our FluidFM solutions bring significant benefits to a wide range of applications in life sciences, biophysics and mechanobiology. Benefit from quantitative volume measurements of injected compounds during drug development, improved CRISPR gene editing by direct delivery into the nucleus, 2.5D nano-printing down to sub-micron levels or single cell adhesion and colloidal probe measurements.
Cytosurge AG develops, manufactures and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the patented hollow FluidFM probes which have apertures down to 300 nm enabling the handling of femtoliter volumes.

Location

Sägereistrasse 25, 8152 Glattbrugg, Schweiz

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2009

  • Number of employees in Switzerland

    10-19